Leukaemia and Lymphoma Treatment in India for Congolese Patients: What It Costs, and How to Decide Well

Author:- Dr. Dheeraj Bojwani Date Created:- 24-08-2026

Childhood leukaemia is one of modern medicine's genuine success stories — in high-income countries, cure rates for the most common form now exceed 90%, using drugs that have existed for decades and are neither exotic nor especially expensive. In 24 years of advising cancer patients, I have found this fact makes the gap in outcomes across much of Sub-Saharan Africa especially striking, because it is not primarily a story about missing medicine. This guide sets out plainly what actually drives that gap, what treatment in India costs against the Western alternatives some patients consider, and what to weigh before deciding.

Healing Journeys of Congolese Patients

Congolese Patients Share Their Experience

Key Takeaways

• The guide highlights a major difference in childhood leukaemia outcomes between high-income countries and much of Sub-Saharan Africa. It reports cure rates of roughly 90% in high-income countries compared with often below 25% across much of Sub-Saharan Africa, despite broadly similar underlying chemotherapy protocols.
• The guide explains that treatment abandonment is a major reason for poorer outcomes. Leukaemia treatment can continue for one to three years, moving through induction, consolidation and maintenance, so stopping treatment early because of cost, distance or misunderstanding can compromise the benefit already achieved.
• The page 3 graphic highlights that Burkitt lymphoma occurs approximately 10 times more frequently in parts of Africa than in high-income countries. The same page gives an indicative treatment range of US$4,000–20,000 in India, compared with US$50,000–150,000 in France/Belgium, US$60,000–180,000 in the UK and US$80,000–250,000 in the US.
• The guide stresses that the headline treatment quotation may not represent the full treatment cost. A written estimate should specify the expected duration of treatment, including therapy that may continue after the initial hospital stay. Patients should understand what treatment will be required after returning home.
• For Congolese patients, the guide recommends sending actual pathology, biopsy and blood-test results, understanding the full treatment duration and planning how maintenance therapy will continue after returning home. It also recommends a 15–20% financial buffer, early medical and attendant visa preparation and a current yellow-fever certificate.
• The guide identifies four warning signs: no clear explanation of treatment duration, no genuine pathology or blood-test results supporting the diagnosis, no plan for maintenance therapy after returning home and pressure to pay the full balance before a complete written treatment plan.

Quick Facts

Author

Dr. Dheeraj Bojwani

Experience

24+ Years

Treatment

Leukaemia & Lymphoma Treatment

Patients

Congolese Patients and Families

Key Assessment

Pathology, biopsy and blood tests

First Step

Confirm the diagnosis and risk classification

Treatment Duration

Often one to three years

Treatment Phases

Induction, consolidation and maintenance

Key Concern

Treatment abandonment

India Cost

US$4,000–20,000 indicative range

Cost Check

Full expected treatment duration included

Financial Buffer

15–20%

Medical Records

Pathology, biopsy and blood-test results

Visa

Paper medical and attendant visa

Entry Requirement

Current yellow-fever certificate

Follow-Up

Maintenance therapy and long-term coordination

Key Warning

Do not plan treatment without understanding the full course

Decision Principle

Choose a treatment pathway that makes completing the full protocol realistically possible.

In Brief

For Congolese patients with leukaemia or lymphoma, the guide recommends focusing on completing the entire treatment course rather than only starting therapy. Patients should confirm the diagnosis, understand whether treatment may continue for one to three years, plan follow-up after returning home and obtain a complete written cost estimate before travelling to India.

One of Medicine's Biggest Gaps

In high-income countries, roughly 90% of children diagnosed with the most common form of leukaemia are cured. Across much of Sub-Saharan Africa, that figure often falls below 25%, even though the underlying chemotherapy protocols are broadly similar and the core drugs involved are neither new nor prohibitively expensive on their own.

This gap is genuinely unusual within oncology. For many cancers, survival differences track access to advanced technology, specialised surgery, or expensive newer drugs. Leukaemia's core treatment protocol has existed in a broadly similar form for decades, and yet the outcome gap remains among the widest of any cancer type covered in this series — a strong signal that something other than the medicine itself is the primary obstacle.

The Same Drugs, the Same Protocols — Often Not Completed

Research into why this gap persists consistently identifies treatment abandonment, families stopping treatment partway through, as the single largest driver of poor outcomes in lower-resource settings. Leukaemia treatment is not a single event; it typically unfolds over two to three years, through distinct phases of induction, consolidation, and maintenance therapy. Interrupting that sequence partway through can undo the benefit of everything completed so far.

A study from southwestern Uganda that spoke directly with caregivers found that money was the most commonly cited reason for stopping treatment early — not disbelief in the treatment, not distance alone, but the accumulated financial strain of a multi-year process. This is a useful reminder that abandonment is rarely a single bad decision; it is usually the result of sustained pressure that eventually becomes unsustainable.

The one fact worth remembering

Not Every Blood Cancer Follows the Same Pattern

Unlike most cancers covered in this series, some blood cancers are actually diagnosed more often in Africa than in high-income countries. Burkitt lymphoma, closely linked to Epstein-Barr virus infection and, in some regions, to malaria, occurs roughly ten times more frequently in parts of Africa than in high-income countries — a genuinely different epidemiological pattern from the "later diagnosis of an equally common disease" story that applies to many other cancers.

What Treatment Costs: DRC Reality vs India vs the West

Cost depends heavily on the specific type of blood cancer and whether a bone marrow transplant becomes necessary, but the relative gap between India and Western options holds fairly consistently.

In India, leukaemia or lymphoma treatment typically costs US$4,000 to US$20,000, depending on the specific diagnosis and treatment needed. In France or Belgium, costs typically run US$50,000 to US$150,000. In the UK, costs range roughly US$60,000 to US$180,000. In the US, the same combination of treatments commonly costs US$80,000 to US$250,000. India's typical price sits at roughly a tenth of the uninsured US figure.

What the number on the quote does not always show

A written estimate should specify the full expected length of treatment, not just the initial induction phase, since leukaemia and lymphoma treatment often continues for a year or more beyond the first hospital stay. In 24 years of reviewing these quotes, I have found disputes almost never concern the headline figure — they concern what it silently left out. Get every line item in writing, and never pay the full balance before treatment begins.

What a Congolese Patient Should Weigh, Specifically

1. Understand the full expected length of treatment from the outset, since leukaemia and lymphoma protocols often run one to three years, not weeks.
2. Send the actual pathology, biopsy, and blood test results, not just a description of symptoms, since precise diagnosis determines the correct protocol.
3. Plan realistically for the full course, including how maintenance therapy might continue after returning home, and how that follow-up will be coordinated.
4. Ask directly what happens if treatment needs to pause for any reason, and how to resume safely rather than abandoning it.
5. Budget in US dollars, with margin. The Congolese franc has weakened considerably against the dollar (roughly CDF 2,300–2,350 per US$1 in mid-2026, and it moves); build in a 15–20% buffer above the initial estimate.
6. Start the visa process early. DRC passport holders need a paper medical visa through the Embassy of India in Kinshasa (Avenue Batetela, Gombe), typically around two weeks once the hospital's invitation letter is ready; apply for an attendant visa at the same time.
7. Confirm your yellow fever certificate is current — mandatory for entry into India, at least 10 days before travel.

Four signals that should make you pause

• No clear explanation of the full expected treatment length from the very first consultation.
• No genuine pathology or blood test results behind the diagnosis.
• No plan for coordinating maintenance therapy once you return home.
• Pressure to pay the full balance before a written, complete treatment plan exists.

Why India Specifically for Leukaemia and Lymphoma Treatment for Congolese Patients?

India operates high-volume haematology and oncology centres with extensive experience delivering complete, multi-year leukaemia and lymphoma protocols, including structured support for patients travelling from abroad to help make full treatment completion realistic. Combined with English-language consultation throughout and hospital accreditation (NABH domestically, JCI internationally) that mirrors the standards used to evaluate hospitals in the US and Europe, India offers a realistic, affordable path to completing the full treatment course that this particular group of cancers genuinely requires, at a cost structure that makes sustaining a multi-year commitment genuinely achievable.

A closing word

Leukaemia and lymphoma are, in the right circumstances, among the most curable of all cancers — but only when the full course of treatment is genuinely completed. What matters most is understanding realistically how long that course will take from the very beginning, and choosing a path that makes seeing it through possible. If you are able to share your pathology and blood test results, I am glad to give a direct, honest view on what your case would involve.

Sources

• 🌐 National Medical Commission of India — verify any surgeon's registration · nmc.org.in
• 🌐 National Accreditation Board for Hospitals & Healthcare Providers (NABH) · nabh.co
• 🌐 Embassy of India, Kinshasa — medical visa requirements · eoikinshasa.gov.in
• 🌐 "Tackling childhood cancer in sub-Saharan Africa," The Lancet Child & Adolescent Health · thelancet.com
• 🌐 "Barriers to timely diagnosis and treatment of childhood cancer in Sub-Sahara Africa" · pmc.ncbi.nlm.nih.gov
• 🌐 World Health Organization — yellow fever vaccination requirements · who.int/health-topics/yellow-fever

Frequently Asked Questions by Congolese Patients about Leukaemia and Lymphoma Treatment in India

How successful can childhood leukaemia treatment be?

The guide reports cure rates of roughly 90% in high-income countries, while outcomes across much of Sub-Saharan Africa are often below 25%.

Why do outcomes differ despite similar chemotherapy?

The guide identifies treatment abandonment, cost, distance and misunderstanding about the need to continue treatment as major barriers to successful completion.

How long can leukaemia treatment take?

Treatment commonly continues through induction, consolidation and maintenance, with some protocols lasting one to three years.

Is Burkitt lymphoma common in Africa?

The guide reports that Burkitt lymphoma occurs approximately 10 times more frequently in parts of Africa than in high-income countries.

What does treatment cost in India?

The guide gives an indicative range of US$4,000–20,000 for leukaemia or lymphoma treatment, depending on the diagnosis and treatment required.

Can treatment costs continue after returning home?

Yes. Maintenance therapy may continue after the initial treatment period in India, so families should establish how follow-up treatment will be coordinated at home.

What medical records should be sent?

Patients should send actual pathology, biopsy and blood-test results, rather than only providing a description of symptoms.

How much financial buffer is recommended?

The guide recommends maintaining a 15–20% buffer above the initial estimate.

What travel documents are important?

Congolese patients should arrange paper medical and attendant visas and ensure their yellow-fever certificate is current before travelling to India.

What are the main warning signs?

Be cautious if the centre cannot clearly explain the full treatment duration, diagnosis, follow-up plan or complete cost, or pressures the family to pay the full balance before receiving a written treatment plan.

Page Summary

This five-page guide explains the large childhood leukaemia outcome gap between high-income countries and Sub-Saharan Africa, the importance of completing multi-year treatment and the different patterns seen with blood cancers such as Burkitt lymphoma. The page 3 chart compares treatment costs across India and Western countries, while page 4 focuses on treatment duration, medical records, follow-up, visas and warning signs.

Citation Block

Field	Information
Topic	Leukaemia & Lymphoma Treatment in India for Congolese Patients
Treatment	Leukaemia & Lymphoma Treatment
Patients	Congolese Patients
Key Assessment	Pathology, biopsy and blood tests
First Step	Confirm diagnosis and risk classification
Treatment Duration	One to three years in many protocols
Treatment Phases	Induction, consolidation and maintenance
Key Concern	Treatment abandonment
India Cost	US$4,000–20,000 indicative range
Cost Check	Full treatment duration clearly specified
Medical Records	Pathology, biopsy and blood-test results
Financial Buffer	15–20%
Visa	Paper medical and attendant visa
Yellow Fever	Current certificate
Follow-Up	Maintenance therapy after returning home
Warning Signs	Unclear treatment duration, inadequate diagnostic records, no follow-up plan or early full-payment pressure
Key Decision	Choose a pathway that supports completion of the full treatment course